# K040868: Sepramesh IP Bioresorbable Barrier - Permanent Mesh

- Pathway: 510(k) (Traditional)
- Applicant: Genzyme Corp.
- Decided: Jun 4, 2004 after 63 days
- Product code: FTM (Mesh, Surgical)
- Device class: 2
- Regulation: 21 CFR 878.3300
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 2 generations back to K971745 (1997). 5 ancestors in all.
34 later devices descend from it; 5 cite it directly.
0 of 40 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K994328: Sepramesh Biosurgical Composite, Model SMBC-XXX, Genzyme Corp. (2000) Summary page 2.
- K002684: Composix E/X Mesh, C.R. Bard, Inc. (2000) Summary page 2.
- K810428: Vicryl, ETHICON, Inc. (1981) Summary page 2.
- K830889: Dexon 'S' Polyglycolic Acid Mesh, Davis & Geck, Inc. (1983) Summary page 2.
- (no number) Bard D Mesh: named in the summary without a submission number

## Most influential descendants
- K053066: Sepramesh IP Bioresorbable Coating/Permanent Mesh (2005), 17 descendants of its own
- K063739: Sepramesh, Model 5959-1214 (2007), 16 descendants of its own
- K062915: Veritas Collagen Matrix (2006), 15 descendants of its own
- K101851: Ventralight ST Mesh (2010), 10 descendants of its own
- K073391: Surgisis Biodesign Tissue Graft (2008), 8 descendants of its own

## Indications for use
Sepramesh Tm IP Bioresorbable Coating - Permanent Mesh is indicated for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.

Source page: https://510kreport.com/device/K040868
Methodology: https://510kreport.com/methodology